CSIMarket
 
Mannkind Corporation  (MNKD)
Other Ticker:  
 
 
Price: $4.4700 $-0.03 -0.667%
Day's High: $4.57 Week Perf: -3.04 %
Day's Low: $ 4.40 30 Day Perf: 24.17 %
Volume (M): 5,811 52 Wk High: $ 5.75
Volume (M$): $ 25,976 52 Wk Avg: $4.08
Open: $4.46 52 Wk Low: $3.17



 Market Capitalization (Millions $) 1,447
 Shares Outstanding (Millions) 324
 Employees 191
 Revenues (TTM) (Millions $) 177
 Net Income (TTM) (Millions $) -31
 Cash Flow (TTM) (Millions $) 83
 Capital Exp. (TTM) (Millions $) 37

Mannkind Corporation
Mannkind Corporation is a biopharmaceutical company that operates in the United States. The company is dedicated to the development and commercialization of therapeutic products for patients with various medical conditions. Specifically, Mannkind Corporation focuses on developing therapeutic products for the treatment of pulmonary arterial hypertension, diabetes and cancer.

One of the main products developed by Mannkind Corporation is Afrezza, a rapid-acting insulin inhalation powder that is used to treat diabetes. Afrezza is an inhalable insulin that works faster than traditional insulin injections and does not require a needle. This product is patented and provides a unique approach to the treatment of diabetes.

Apart from Afrezza, Mannkind Corporation has a number of other products in development. For pulmonary arterial hypertension, the company is developing TRE-Xi, an inhaled treatment that targets the smooth muscle cells in the pulmonary arteries. Additionally, Mannkind Corporation is also developing new technology for the delivery of inhaled drugs, which is known as the Technosphere platform technology. This proprietary platform allows for the delivery of drugs using inhalation and offers enhanced product performance and increased stability.

The company has also established various collaborations with other pharmaceutical companies to develop and commercialize its products. For instance, Mannkind Corporation has a co-promotion agreement with Sanofi-Aventis for the promotion of Afrezza globally. Similarly, the company has also entered into partnerships with United Therapeutics to develop therapies for the treatment of pulmonary arterial hypertension.

Mannkind Corporation was founded in 1991 and is headquartered in California. The company has a workforce of approximately 200 employees and has a market capitalization of approximately $255 million USD. Mannkind Corporation is listed on the NASDAQ stock exchange under the ticker symbol MNKD.


   Company Address: 1 Casper Street Danbury 6810 CT
   Company Phone Number: 661-5000   Stock Exchange / Ticker: NASDAQ MNKD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Groundbreaking INHALE-3 Study Shows Afrezza Outperforms MDI and Insulin Pumps in Initial Meal Challenge Results for Diabetes Management

Published Mon, Mar 11 2024 10:05 AM UTC

INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza Head-to-Head with Multiple Daily Injections (MDI) and Insulin PumpsRecently, the INHALE-3 study released its initial meal challenge results, which compared the effectiveness of Afrezza, an inhalable insulin, with multiple daily injections (MDI) and insulin pumps. This groundbreaking study aims to provide valua...

Clinical Study

Breathing New Life into Pediatric Diabetes: MannKind's Afrezza Enrolls Success in INHALE-1 Trial

Published Thu, Feb 15 2024 11:05 AM UTC

for MannKind Corporation, a renowned pharmaceutical company, has recently announced the successful completion of the enrollment goal for their INHALE-1 Pediatric Diabetes Trial involving the utilization of Afrezza. This groundbreaking development holds significant implications for the treatment of pediatric diabetes and the future landscape of therapeutics in this field.Fa...

Mannkind Corporation

Mannkind Corporation Surpasses Industry Competitors with Impressive Financial Results and Accelerated Revenue Growth

Mannkind Corporation, a major player in the pharmaceutical preparations sector, has displayed impressive financial results for the fiscal period closing on September 30, 2023. The company has managed to achieve profitability with earnings per share (EPS) of $0.01, a significant improvement compared to a loss of $0.06 per share in the previous year. The positive turnaround in EPS is also evident when compared to the previous reporting season, where EPS stood at -$0.02 per share.
One of the key factors behind Mannkind Corporation's success is its substantial increase in revenue. The company witnessed a remarkable growth of 56.14%, with revenue reaching $51.25 million in the same reporting season, compared to $32.83 million in the previous year. Moreover, the sequential revenue growth from the previous quarter showcases a 5.435% increase from $48.61 million. This outstanding performance far surpasses other companies in the Major Pharmaceutical Preparations sector, which reported only 1.86% top-line growth during the same period.

Mannkind Corporation

Significant Decrease in Losses: Mannkind Corporation Reports Promising Financial Performance in Q2 2023

Mannkind Corporation, a pharmaceutical company specializing in the development of therapeutic products, has shown considerable improvements in its financial performance for the April to June 30, 2023 span. The company managed to decrease its loss per share from $-0.11 to $-0.02 when compared to the previous year. Additionally, the earnings per share (EPS) improved to $-0.04 per share from the prior reporting period.
A significant highlight was the surge in revenue, which showed an impressive increase of 157.283%. The company reported revenue of $48.61 million, compared to $18.89 million in the corresponding period a year before. Sequentially, revenue also improved by 19.655% from $40.63 million.






 

Mannkind's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com